Paper Review Records
All Paper Review Records
20 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
186
days
Dysregulated KMT2D mutant targeting immunogenic rewiring to overcome epigenetic entropy promotes follicular lymphomagenesis
AuthorsYuqian Zhu; Jingwei Yao; Yuelong Jiang; Qian Lai; Qinwei Chen; Jingxing Zhang; Manman Deng; Zhijuan Lin; Yiming Luo; Zhifeng Li; Long Liu; Zhong Zheng; Jie Zha; Bing Xu
Affiliations1. Department of Hematology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China; 2. Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, China; 3. Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
199
days
Multimodal AI and single-cell transcriptomics integrate to construct a histopathological prognostic model for bladder cancer, revealing the RTN3-glycolysis axis in chemoresistance
AuthorsShunli Yu; Yingjian Wang; Dapeng Feng; Xinglai Dai; Yongbo Luo; Jianing Wang; Zihe Wang; Fuxiang Chen; Haoran Wang; Fengyan Tian; Xuejia Zhai; Chaohui Gu
Affiliations1. Department of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; 2. Department of Endocrinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; 3. Department of Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; 4. Department of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
211
days
Combination of PARPi and topoisomerase I inhibitors is highly effective in olaparib-resistant ovarian cancer
AuthorsM. Chiappa; V. Villa; F. Sias; C. Grasselli; L. Sala; S. Canesi; M. Marabese; S. Mason; D. Dibitetto; R. Fruscio; G. Damia
Affiliations1. Laboratory of Preclinical Gynecological Oncology, Department of Experimental Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy; 2. Gynaecology Oncology Unit, Humanitas San Pio X, Milan, Italy; 3. Department of Biomedical Sciences, University of Sassari, Sassari, Italy; 4. Immunopharmacology Unit, Department of Experimental Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy; 5. Mouse & Animal Pathology Laboratory (MAPLab), Department of Veterinary Medicine and Animal Sciences, Fondazione UniMi, University of Milano, Lodi, Italy; 6. Laboratory of Molecular Pharmacology, Department of Experimental Oncology, Istituto Di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy; 7. Molecular Oncology & DNA Damage Response Unit, Department of Experimental Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy; 8. UO Gynecology, Department of Medicine and Surgery, Fondazione IRCCS San Gerardo dei Tintori, University of Milan-Bicocca, Monza, Italy
113
days
CD84 expression stratifies venetoclax response and reveals a targetable vulnerability in resistant acute myeloid leukemia
AuthorsXuemei Wang; Xiangjie Lin; Tianyi Chen; Yi Chen; Huafeng Wang; Yinghui Zhu
Affiliations1. State Key Laboratory of Cardiovascular Diseases and Medical Innovation Center, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China; 2. Frontier Science Center for Stem Cell Research, Tongji University, Shanghai, China; 3. Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China; 4. Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies, Hangzhou, PR China; 5. Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, China
153
days
Tumor-intrinsic NSUN2 orchestrates immunosuppression in lung adenocarcinoma via the m 5 C-HDAC8-CCL5 axis
AuthorsWangyang Meng; Tong Lu; Mingyuan Du; Xin Dai; Yichao Han; Yingyi Li; Haimin Xu; Biaolong Yang; Zeyu Wang; Hailei Du; Keman Liao; Xinnan Liu; Yidan Sun; Cui Yang; Dong Dong; Yan Yan; Wei Guo; Bin Li; Hecheng Li
Affiliations1. Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 2. Center for Immune-Related Diseases, Shanghai Institute of Immunology, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 3. Institute of Respiratory Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 4. Clinical Trial Ward, Shanghai Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 5. Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 6. Department of Medical Oncology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China; 7. Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China; 8. Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 9. Department of Respiratory and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
193
days
Chimeric antigen receptor (CAR)-T cell therapy for solid tumors in pediatric patients: current breakthroughs, dilemmas, and strategies
AuthorsYumiao Mai; Ziwen Wang; Juan Wang; Mengjia Song; Tong Xiang; Yuelin He; Alex H. Chang; Yizhuo Zhang
Affiliations1. Department of Pediatric Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China; 2. State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China; 3. Department of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, China; 4. Nanfang-Chunfu Children’s Institute of Hematology and Oncology, TaiXin Hospital, Dongguan, China; 5. Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai, China; 6. YaKe Center for Cell Engineering and Therapeutics, Shanghai, China
82
days
Clinical outcomes and molecular features of CEBPA -mutated MPAL: a multi-center case series
AuthorsYirong Wu; Weijie Luo; Na An; Xiaohan Zhang; Jianyun Li; Yixuan Cao; Yunxin Zeng; Peng Ke; Lu Liu; Linlin Yang; Changru Luo; Shiyu Chen; Sitian Yang; Haoyu Peng; Xiaoqing Li; Jingchao Fan; Rujiao Dong; Bingbing Wen; Xin Du; Lixin Wang; Guangyang Weng
Affiliations1. Department of Hematology and Shenzhen Bone Marrow Transplantation Public Service Platform, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China; 2. Shenzhen Institute of Hematology, Shenzhen Second People’s Hospital, Shenzhen University Health Sciences Center, The First Affiliated Hospital of Shenzhen University, Shenzhen, China; 3. Hematology Department, People’s Hospital of Shenzhen Bao an District, Shenzhen, China; 4. Department of Hematology, Shenzhen People’s Hospital, Shenzhen, China; 5. Department of Hematology, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China; 6. Department of Hematology and Oncology, Hematology Institution, Base for International Science and Technology Cooperation, Carson Cancer Stem Cell Vaccines R&D Center, International Cancer Center, Shenzhen University General Hospital, International Cancer Center, Haoshi Cell Therapy Institute of Shenzhen University, Shenzhen University Medical School, Shenzhen University, Shenzhen, China
105
days
Single-cell mapping of thymus-dependent naïve t-cell regeneration reveals CD61-associated states after hematopoietic stem cell transplantation
AuthorsFangqing Zhang; Xinya Jiang; Shuang Fan; Bixia Wang; Zhigui Wu; Jingrui Zhou; Qi Zhang; Zhiyu Zhang; Jianing Tang; Zheng-Li Xu; Yu Wang; Xiao-Jun Huang; Huidong Guo
Affiliations1. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Disease, Peking University People’s Hospital, Peking University Institute of Hematology, Peking University, Beijing, China; 2. Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China
105
days
Novel agents and evolving strategies in Waldenström macroglobulinemia: clinical trial updates from ASH 2025
AuthorsYujing Liang; Xinyi Deng; Ziwen Wang; Chuanmiao Xie; Lie Zheng; He Huang; Shaohan Yin; Huageng Huang
Affiliations1. Department of Radiology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China; 2. Department of Dermatology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, P.R. China; 3. Department of Pediatric Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China; 4. Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China
235
days
Spatial multi omic profiling maps hypoxia-driven pro-fibrotic SPP1 + macrophages underpinning immune escape and TACE resistance in hepatocellular carcinoma
AuthorsFansen Ji; Hao Chen; Boyang Wu; Ying Xiao; Jiawei Zhang; Jianghui Yang; Weihua Yan; Xiaojuan Wang; Bingjun Tang; Huan Li; Siyu Wu; Quan He; Hao Liu; Haoming Xia; Xinquan Liu; Yibo Gao; Pengfei Wang; Shizhong Yang; Jiahong Dong
Affiliations1. Tsinghua-Peking Center for Life Sciences, Beijing, China; 2. Hepatopancreatobiliary Center, Key Laboratory of Digital Intelligence Hepatology (Ministry of Education), School of Clinical Medicine, Tsinghua Medicine, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China; 3. Department of Pathology, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China; 4. Health Management Center, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China; 5. Cold Spring Biotech Corp., Beijing, China; 6. Institute for Organ Transplant and Bionic Medicine, Beijing Key Laboratory of Liver Transplantation and Bionic Manufacturing, Tsinghua University, Beijing, China; 7. Central Laboratory and Shenzhen Key Laboratory of Epigenetics and Precision Medicine for Cancers, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days